NanoSmart Begins Development of New Drug Delivery Platform for Cancer
NanoSmart Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in
“Our new location gives us a physical presence in
NanoSmart is developing a patented, novel anti-tumor-targeting platform based on fully human autoimmune antibodies. These antibodies target areas of necrosis found in many different types of cancer. NanoSmart’s drug delivery system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy. By combining these antibodies with different cancer drugs, NanoSmart has the potential to develop a very large number of novel biopharmaceutical products.
NanoSmart Pharmaceuticals, Inc., is a privately held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumortargeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer.
Total Page Views: 1668
